Centrexion Therapeutics Corp., of Boston, which is focused on developing non-opioid, nonsteroidal therapeutics for the treatment of chronic pain, said the FDA has granted fast track designation to CNTX-4975 for the treatment of pain associated with knee osteoarthritis.